Beginning its ninth year as an industry event, BioPharm America™ creates a robust exchange among hundreds of executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from mature to startup. The event brings dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. It is a pure partnering event focused on one-to-one meetings driven by the partneringONE® software platform that schedules meetings and provides each participant with a dynamic personalized agenda and regular alerts for further meeting opportunities. The backdrop for this intensive business development activity is a three-day conference program that features leading executives from across the life science industry. To help bring attention to early stage projects and small entrepreneurial companies BioPharm America features a full Biotech Startup Day program. This is specifically designed for early stage projects and young companies to get on the radar of the global life science community and to make the connections that matter. At past BioPharm America events, held in Boston each September, panel discussions included licensing, investment and business development executives from Amgen, AstraZeneca, Bayer HealthCare, Biogen Idec, Boehringer Ingelheim, Genentech, Sanofi/Genzyme, Gilead, Ironwood, Johnson & Johnson Innovation, Merck, Novo Nordisk, Nycomed, Pfizer, and Shire. The event attracted 850+ delegates from 525 companies who participated in 2,350+ scheduled one-to-one meetings. For more information and online registration please visit our conference website at www.ebdgroup.com/bpa.